Clindamycin

Sold as Dalacin vc, Clindahexal, Pharma-q clindamycin, Dalacin vaginal ovule, Clindaspen, Clindoxyl, Klidar, Lindam, Clindamycin m/m foamglenmark, Clindamycin equity, Dalacin c, Clindamycin fresenius, Dalacin t

S4Read from the PI-PIL document and verified

C₁₈H₃₃ClN₂O₅S425.00 g/mol

(2S,4R)-N-[(1S,2S)-2-Chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide

Drag to rotate. Structure from PubChem CID 446598.

Loading Wikipedia summary

Registration

Applicants: 9
Registrations: 17
Schedule source: SAHPRA documentation

Applicants and registrations

Applicant	Brands	Dosages	Registrations	Schedule	Leaflets
Pfizer Laboratories (Pty) LtdCertificate held by Pfizer laboratories	Dalacin vc, Dalacin vaginal ovule, Dalacin c, Dalacin t	20 mg, 150 mg, 600 mg, lotion	270292, 360007, C0001, F0169, Y0326	S4	PI PIL
Sandoz South Africa (Pty) LtdCertificate held by Sandoz SA (Pty) Ltd1 of 2 cancelled	Clindahexal	150 mg, 300	320038, 320039	S4	PI PIL
Pharma-q Holdings (Pty) Ltd	Pharma-q clindamycin	600 mg/4 ml	320502	S4	None
Pharmacare limited û woodmead	Clindaspen	300 mg, 600 mg	420108, 420568	S4	None
Glaxosmithkline South Africa (Pty) LimitedCancelled	Clindoxyl	gel	420441	S4	None
Aurogen South Africa (Pty) Ltd	Klidar, Lindam	Not stated	520029, 520030	S4	None
Glenmark Pharmaceuticals South Africa (Pty) Ltd	Clindamycin m/m foamglenmark	1 %	530558	S4	None
Equity Pharmaceutical (Pty) LtdCertificate held by Equity Pharmaceuticals (Pty) Ltd	Clindamycin equity	150 mg, 300	560105, 590149	S4	PI PIL
Fresenius Kabi Manufacturing SA (Pty) Ltd	Clindamycin fresenius	600 mg/4 ml	Y0254	S4	None

Variants

Product	Strength and form	Registration	Status	Schedule	Leaflets
Dalacin vc EACH GRAM CONTAINS CLINDAMYCIN PHOSPHATE EQUIVALENT TO 20 mg CLINDAMYCIN	20 mgVaginal cream	27029227/20.1.1/0292Approved 12 December 2024	Registered	S4	PI PIL
Clindahexal 150 EACH CAPSULE CONTAINS CLINDAMYCIN 150,0 mg	150 mgCapsules	32003832/20.1.1/0038Approved 11 April 2023	Registered	S4	PI PIL
Clindahexal 300 EACH CAPSULE CONTAINS CLINDAMYCIN HYDROCHLORIDE EQUIVALENT TO CLINDAMYCIN 300,0 mg	300	32003932/20.1.1/0039	Cancelled	S4	None
Pharma-q clindamycin injection 600 mg/4 ML EACH 4,0 ml SOLUTION CONTAINS CLINDAMYCIN PHOSPHATE EQUIVALENT TO CLINDAMYCIN 600,0 mg	600 mg/4 mlInjection	32050232/20.1.1/0502	Registered	S4	None
Dalacin vaginal ovule EACH VAGINAL SUPPOSITORY CONTAINS CLINDAMYCIN PHOSPHATE EQUIVALENT TO CLINDAMYCIN 100,0 mg	Not listed	36000736/20.1.1/0007	Registered	S4	None
Clindaspen 600 MG EACH 1,0 ml SOLUTION CONTAINS CLINDAMYCIN PHOSPHATE EQUIVALENT TO CLINDAMYCIN 150,0 mg	600 mg	42010842/20.1.1/0108	Registered	S4	None
Clindoxyl gel EACH 100,0 g GEL CONTAINS BENZOYL PEROXIDE 6,670 gCLINDAMYCIN PHOSPHATE EQUIVALENT TO CLINDAMYCIN 1,0 g	Gel	42044142/13.11/0441	Cancelled	S4	None
Clindaspen 300 MG EACH 1,0 SOLUTION CONTAINS CLINDAMYCIN PHOSPHATE EQUIVALENT TO CLINDAMYCIN 150,0 mg	300 mg	42056842/20.1.1/0568	Registered	S4	None
Klidar EACH CAPSULE CONTAINS: CLINDAMYCIN HYDROCHLORIDE USP EQUIVALENT TO CLINDAMYCIN 150 mg	Not listed	52002952/20.1.1/0029	Registered	S4	None
Lindam EACH CAPSULE CONTAINS: CLINDAMYCIN HYDROCHLORIDE USP EQUIVALENT TO CLINDAMYCIN 150 mg	Not listed	52003052/20.1.1/0030	Registered	S4	None
Clindamycin 1 % m/m foamglenmark EACH 1,0 g OF FOAM CONTAINS CLINDAMYCIN PHOSPHATE 10,0 mg	1 %	53055853/20.1.6/0558	Registered	S4	None
Clindamycin equity EACH CAPSULE CONTAINS CLINDAMYCIN HYDROCHLORIDE EQUIVALENT TO CLINDAMYCIN 150,0 mg	150 mgCapsule	56010556/20.1.1/0105Approved 23 May 2023	Registered	S4	PI PIL
Clindamycin 300 equity EACH CAPSULE CONTAINS: CLINDAMYCIN HYDROCHLORIDE EQUIVALENT TO CLINDAMYCIN 300,0 mg	300	59014959/20.1.1/0149	Registered	S4	None
Dalacin c 150 MG EACH CAPSULE CONTAINS CLINDAMYCIN HYDROCHLORIDE EQUIVALENT TO 150 mg CLINDAMYCIN	150 mgCapsule	C0001C/20.1.1/1Approved 17 January 2022	Registered	S4	PI PIL
Dalacin c 600 MG EACH 4 ml CONTAINS CLINDAMYCIN PHOSPHATE EQUIVALENT TO 600,0 mg CLINDAMYCIN	600 mg	F0169F/20.1.1/169	Registered	S4	None
Clindamycin 600 mg/4 ML fresenius EACH 4,0 ml SOLUTION CONTAINS CLINDAMYCIN PHOSPHATE EQUIVALENT TO 600,0 mg CLINDAMYCIN	600 mg/4 ml	Y0254Y/20.1.1/254	Registered	S4	None
Dalacin t lotion EACH 1 g LOTION CONTAINS CLINDAMYCIN PHOSPHATE EQUIVALENT TO CLINDAMYCIN 10 mg	Lotion	Y0326Y/20.1.6/326	Registered	S4	None

Regulatory status

Where S4 sits on the scale

S0S1S2S3S4S5S6S7S8

Prescription-only medicine.

Schedule 4 covers most ordinary prescription medicines. You need a prescription from an authorised prescriber, such as a doctor or dentist, and a pharmacist dispenses it. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.

Schedule S4, read from the product's PI-PIL leaflet.

Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.

Consolidated Schedules listings for Clindamycin phosphate equivalent to clindamycin

S4: Clindamycin
Consolidated Schedules 06 July 2026, line 5840

Pharmacological class: Broad and medium spectrum antibiotics. (class 20.1.1)

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

SAHPRA documents

Schedule verified from official documents

Schedule Verification

Dalacin vc, Pfizer Laboratories (Pty) Ltd is scheduled S4 in its official SAHPRA documents, read with 90% confidence.

Professional information (PI)For healthcare professionalsDalacin vc, Pfizer Laboratories (Pty) Ltd Patient information leaflet (PIL)For patients and carersDalacin vc, Pfizer Laboratories (Pty) Ltd

These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.

Research articles

Loading PubMed articles

Background